PROKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
PROKIDNEY CORP.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$1.40+0.06 (+4.89%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.58 (−53.03%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
PROKIDNEY CORP. grew revenue 55.2% to $818.00K over the twelve months to Jun 30, 2026. Free cash flow was -$159.73M.
Revenue
$818.00K
+55.2% vs. a year earlier
Operating income
-$177.22M
TTM Q2 2026
Free cash flow
-$159.73M
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $818.00K
- Net income
- -$84.16M
- Free cash flow
- -$159.73M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
$818.00K+55.2% YoY
Operating income
-$177.22M
Net income
-$84.16M
EPS, diluted
–
Free cash flow
-$159.73M
Reported periodTrailing twelve months